Introduction Since its addition to the Revised European–American Lymphoma classification, in 1994, mantle cell lymphoma (MCL) has been recognized as carrying both features of indolent lymphoma (incurable) and a more aggressive course with short response to standard chemotherapy and common chemoresistance over time leading to very poor long-term prognosis. The disease presents typically in the elderly male population, with advanced-stage and constant extranodal involvement. There is still no consensus in the treatment of MCL; dose-intensification approaches with or without stem cell transplantation are commonly used in younger patients (